Review Article

Is End-Stage Ankle Arthrosis Best Managed with Total Ankle Replacement or Arthrodesis? A Systematic Review

Robert W. Jordan, Gurdip S. Chahal, and Anna Chapman

1 University Hospitals Coventry & Warwickshire, Clifford Bridge Road, Coventry CV2 2DX, UK
2 Birmingham Heartlands Hospital, Bordesley Green East, Birmingham B9 5SS, UK

Correspondence should be addressed to Robert W. Jordan; robert.jordan@doctors.org.uk

Received 24 May 2014; Accepted 12 August 2014; Published 21 August 2014

Copyright © 2014 Robert W. Jordan et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Introduction. End-stage ankle osteoarthrosis is a debilitating condition. Traditionally, ankle arthrodesis (AA) has been the surgical intervention of choice but the emergence of total ankle replacement (TAR) has challenged this concept. This systematic review aims to address whether TAR or AA is optimal in terms of functional outcomes. Methods. We conducted a systematic review according to PRISMA checklist using the online databases Medline and EMBASE after January 1, 2005. Participants must be skeletally mature and suffering from ankle arthrosis of any cause. The intervention had to be an uncemented TAR comprising two or three modular components. The comparative group could include any type of ankle arthrodesis, either open or arthroscopic, using any implant for fixation. The study must have reported at least one functional outcome measure. Results. Of the four studies included, two reported some significant improvement in functional outcome in favour of TAR. The complication rate was higher in the TAR group. However, the quality of studies reviewed was poor and the methodological weaknesses limited any definitive conclusions being drawn. Conclusion. The available literature is insufficient to conclude which treatment is superior. Further research is indicated and should be in the form of an adequately powered randomised controlled trial.

1. Introduction

End-stage ankle osteoarthrosis is a debilitating condition that results in functional limitations and a poor quality of life [1]. The incidence of symptomatic osteoarthrosis of the ankle has been estimated to be 47.7/100,000 in the United Kingdom [2]. More than 70% is related to posttraumatic osteoarthrosis [1, 3] with the majority of the remainder being primary arthritis, inflammatory arthritis, or secondary to osteonecrosis. Mild to moderate ankle arthritis can often be managed with ankle foot orthoses and a rocker-bottom shoe [4]. When surgical intervention is indicated, ankle arthrodesis (AA) has traditionally been used. However, the development of total ankle replacement (TAR) has challenged arthrodesis as the treatment of choice for ankle arthrosis [5–7].

AA has been shown to give good results in multiple papers [8–10]. Various techniques have been used which include cannulated screws, plate fixation, retrograde nail, and external fixation. The main drawback of the procedure is the high rate of later arthrosis in adjacent joints, reported between 10 and 60% [11–13]. This results in a subsequent subtalar fusion rate at 5 years of 2.8% which is higher than the 0.7% after TAR [14]. Additional complications associated with AA include wound infection (3–25%), nonunion (10–20%), and malalignment [15, 16].

TAR is still evolving [17] but has the potential advantage to preserve range of motion, restore gait, and, thus, protect adjacent articulations [18]. The results from first generation ankle prosthesis were disappointing with stiffness, wound complications, loosening, malalignment, impingement, and instability cited as causes of failure [7, 19–21]. Newer prosthesis is uncemented, comprises two or three modular components, and has improved outcomes. A recent systematic review reported 89% survival of 7942 TARs at 10 years and
Table 1: Search strategy for Medline.

| Number | Search term                                      | Results |
|--------|--------------------------------------------------|---------|
| 1      | exp Ankle Joint/or exp Ankle/                    | 16259   |
| 2      | exp Arthroplasty, Replacement/or exp Arthroplasty/or exp Arthroplasty, Replacement, Ankle/ | 37169   |
| 3      | exp Arthrodesis/                                 | 22930   |
| 4      | 1 and 2 and 3                                    | 141     |
| 5      | limit 4 to (english language and humans)         | 128     |
| 6      | limit 5 to yr = “2005–Current”                   | 88      |

2. Methods

We conducted a systematic review of the literature using the online databases Medline and EMBASE. The review was performed and reported according to the PRISMA checklist. The search strategy used for the Medline search is shown in Table 1 and this was modified for searching EMBASE. The searches were carried out on January 15, 2014, and limited to papers available in English. The search was limited to papers published after January 1, 2005, as the previous systematic review published in 2007 included papers prior to this date [24].

Inclusion criteria were applied. Participants must be skeletally mature and suffering from ankle arthrosis of any cause deemed severe enough to warrant either TAR or AA by the treating surgeon. The intervention had to be an uncemented TAR comprising two or three modular components. The comparative group could include any type of ankle arthrodesis, either open or arthroscopic, using any implant for fixation. The study must have reported at least one functional outcome measure. Studies were excluded if no comparative group was analysed or if the study participants were divided into more than two groups. In addition, only primary research was considered for review with any abstracts, comments, review articles, and technique articles excluded. Eligibility of studies was assessed independently by two authors (R.J. and G.C.) who also appraised the included studies against the STROBE statement [25]. If there was any disagreement between the authors in assigning a score to each paper appraised, a third independent reviewer (A.C.) made the final decision.

3. Results

The Medline search revealed 88 and the EMBASE search 126 results. Figure 1 shows a flow diagram of the review process including the reasons for exclusion at different stages of the process. Concise details of the included studies are given in Table 2 and the appraisal against STROBE statement [25] is given in Table 3. The reasons for exclusion of the 10 articles at full paper review stage are given in Table 4.

Of the four studies included, three were level III retrospective comparative studies and the other was a level II prospective comparative study. The optimal study design when comparing two treatment modalities is a randomised controlled trial (RCT) as this allows for minimisation of bias. The main limitation that is common to all four studies reviewed is the lack of randomisation; this risks selection bias.
| Study                  | Study Design                  | Population                                      | Intervention                                      | Comparator                                      | Outcome measures (primary in bold)                                                                 | Follow-up period | Significant results                                      |
|-----------------------|-------------------------------|-------------------------------------------------|--------------------------------------------------|-------------------------------------------------|---------------------------------------------------------------------------------------------------|-----------------|----------------------------------------------------------|
| Schuh et al., 2012    | Retrospective comparative     | Adults with ankle osteoarthritis who have       | HINTEGRA prosthesis—uncemented 3-component TAR  | Arthrodesis with 3 * cannulated screws (n = 21) | Patient satisfaction Sports and activity questionnaire Halasi ankle score UCLA activity score      | 34.5 months    | No significant results                                    |
| et al., 2012          | study—level III              | failed conservative treatment                   | (n = 20)                                        |                                                  | AOFAS                                                                                             |                 |                                                          |
| Esparragoza et al.,   | Prospective comparative      | Adult primary or secondary ankle arthritis      | Ankle Evolution System prosthesis—uncemented    | Open arthrodesis with bone graft and either     | Improved results in TAR group: AOFAS (P = 0.048) SF-36 (P = 0.026)                              | 24 months       |                                                          |
| 2011                  | study—level II               |                                                  | 3-component TAR (n = 14)                         | external fixator, screw fixation, or retrograde |                                                                                                  |                 |                                                          |
| et al., 2011          |                               |                                                  |                                                  | calcaneal nail (n = 16)                          |                                                                                                  |                 |                                                          |
| Krause et al., 2011   | Retrospective comparative    | Adults with primary or secondary arthritis,     | TAR with one of four uncemented prosthesis:    | Open or arthroscopic arthrodesis (n = 47)       | Higher complication rate with TAR 54% versus 26% (P = 0.003) Higher severity of COFAS in TAR     | Mean 37 months |                                                          |
| et al., 2011          | study—level III              | revision of TAR to AA included                  | agility (two components), mobility (three     |                                                  | group                                                                                             |                 |                                                          |
| et al., 2010          | Retrospective comparative    | Adult posttraumatic or primary ankle osteoarthritis | components), STAR, HINTEGRA (n = 114)          |                                                  |                                                                                                  |                 |                                                          |
| et al., 2010          | study—level III              |                                                  |                                                  |                                                  |                                                                                                  |                 |                                                          |
| et al., 2010          |                               |                                                  |                                                  |                                                  |                                                                                                  | 4.2 years       |                                                          |
| et al., 2010          |                               |                                                  |                                                  |                                                  |                                                                                                  |                 |                                                          |
| Item number | Recommendation | Schuh et al., 2012 [26] | Esparragosa et al., 2011 [27] | Saltzman et al., 2010 [29] | Krause et al., 2011 [28] |
|-------------|----------------|--------------------------|-----------------------------|---------------------------|--------------------------|
| **Title and abstract** | (a) Indicate the study’s design with a commonly used term in the title or the abstract. (b) Provide in the abstract an informative and balanced summary of what was done and what was found. | No | Yes | No | No |
| **Introduction** | | Yes | Yes | Yes | Yes |
| **Background/rationale** | Explain the scientific background and rationale for the investigation being reported. | Yes | Yes | Yes | Yes |
| **Objectives** | State specific objectives, including any prespecified hypotheses. | Yes | Yes | Yes | Yes |
| **Methods** | Present key elements of study design early in the paper. | No | Yes | Yes | Yes |
| **Study design** | Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection. (a) Cohort study—give the eligibility criteria and the sources and methods of selection of participants. Describe methods of follow-up. Case-control study—give the eligibility criteria and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls. | Yes | Yes | Yes | Yes |
| **Setting** | | No | No | No | Yes |
| **Participants** | Cross-sectional study—give the eligibility criteria and the sources and methods of selection of participants. (b) Cohort study—for matched studies, give matching criteria and number of exposed and unexposed. Case-control study—for matched studies, give matching criteria and the number of controls per case. | n/a | n/a | n/a | n/a |
| **Variables** | Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable. For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group. | Yes | Yes | Yes | Yes |
| **Data sources/measurement** | | No | No | No | Yes |
| **Bias** | Describe any efforts to address potential sources of bias. | No | No | No | Yes |
| **Study size** | Explain how the study size was arrived at. | No | No | No | No |
| **Quantitative variables** | Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why. | Yes | No | Yes | Yes |
### Table 3: Continued.

| Item number | Recommendation | Schuh et al., 2012 [26] | Esparragoza et al., 2011 [27] | Saltzman et al., 2010 [29] | Krause et al., 2011 [28] |
|-------------|----------------|-------------------------|-----------------------------|--------------------------|-------------------------|
| 12 | (a) Describe all statistical methods, including those used to control for confounding. | Yes | Yes | Yes | Yes |
| | (b) Describe any methods used to examine subgroups and interactions. | n/a | Yes | n/a | n/a |
| | (c) Explain how missing data were addressed. | No | n/a | No | n/a |
| | (d) **Cohort study**—if applicable, explain how loss to follow-up was addressed. **Case-control study**—if applicable, explain how matching of cases and controls was addressed. | No | n/a | No | n/a |
| Statistical methods | **Cross-sectional study**—if applicable, describe analytical methods taking account of sampling strategy. | n/a | n/a | n/a | n/a |
| | (e) Describe any sensitivity analyses. | n/a | n/a | n/a | n/a |
| 13 | (a) Report numbers of individuals at each stage of study—for example, numbers of potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed. | No | No | Yes | Yes |
| | (b) Give reasons for nonparticipation at each stage. | No | n/a | Yes | Yes |
| | (c) Consider use of a flow diagram. | No | No | No | No |
| | (a) Give characteristics of study participants (e.g., demographic, clinical, and social) and information on exposures and potential confounders. | No | Yes | Yes | Yes |
| Descriptive data | (b) Indicate number of participants with missing data for each variable of interest. | No | No | No | No |
| | (c) **Cohort study**—summarise follow-up time (e.g., average and total amount). **Case-control study**—report numbers of outcome events or summary measures over time. | Yes | Yes | Yes | Yes |
| Outcome data | **Cohort study**—report numbers in each exposure category, or summary measures of exposure. | No | No | No | No |
| | **Cross-sectional study**—report numbers of outcome events or summary measures. | No | No | No | No |
| | (a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (e.g., 95% confidence interval). Make clear which confounders were adjusted for and why they were included. | No | No | No | No |
| Main results | (b) Report category boundaries when continuous variables were categorized. | n/a | n/a | n/a | n/a |
| | (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period. | n/a | n/a | n/a | n/a |
| Other analyses | Report other analyses done—for example, analyses of subgroups and interactions and sensitivity analyses. | n/a | n/a | n/a | n/a |
Table 3: Continued.

| Item number | Recommendation                                                                 | Schuh et al., 2012 [26] | Esparragóra et al., 2011 [27] | Saltzman et al., 2010 [29] | Krause et al., 2011 [28] |
|-------------|----------------------------------------------------------------------------------|-------------------------|------------------------------|----------------------------|-------------------------|
| Discussion  |                                                                                 |                         |                              |                            |                         |
| Key results | Summarise key results with reference to study objectives.                        | Yes                     | Yes                          | Yes                        | Yes                     |
| Limitations | Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias. | Yes                     | No                           | Yes                        | Yes                     |
| Interpretation | Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant lines of evidence. | Yes                     | No                           | Yes                        | Yes                     |
| Generalisability | Discuss the generalisability (external validity) of the study results.       | No                      | No                           | No                         | No                      |
| Other information |                                                                 |                         |                              |                            |                         |
| Funding     | Give the source of funding and the role of the funders in the present study and, if applicable, in the original study on which the present paper is based. | No                      | No                           | No                         | Yes                     |
with the uneven allocation of confounding factors between the groups. In addition, as none of the studies reviewed defined a primary outcome measure or included a power calculation, uncertainty is present as to whether any of the studies was sufficiently powered to show a significant difference in any recorded outcome measure.

Schuh et al., 2012. Schuh et al. [26] performed a retrospective review of 63 patients that underwent either TAR, using a HINTEGRA prosthesis (Newdeal SA, Lyon, France), or AA, using 3 cannulated screws. No significant difference was found between the two groups in terms of activity level, participation in sport, or American Orthopaedic Foot and Ankle Society (AOFAS) hindfoot score. The surgery was performed by a single, fellowship trained surgeon between 1998 and 2006. Of the 63 patients assessed, only 41 were included for analysis. The 16% loss to follow-up forms a high proportion and the majority (70%) of these were in the AA group. The reason these patients refused follow-up is not known and their exclusion may have skewed results. Minimal details of the inclusion criteria are stated and whether patients with arthrosis of any cause were included is not clear. Clarity is required to decide whether results are applicable to other populations. In addition, no mention is given as to whether assessments were performed by an independent observer or the postoperative physiotherapy regimen was consistent between the two groups.

Esparragoza et al., 2011. Esparragoza et al. [27] performed a prospective comparative study of 30 patients. Surgery was performed by a total of 6 senior staff members of whom 3 performed all of the TAR and 3 all of the AA. All patients undergoing TAR had the Ankle Evolution System implant (Biomet, Nimes, France) inserted but arthrodesis was performed by three different techniques. A statistically significant improvement in SF-36 (P = 0.048) and SF-36 (P = 0.026) in the TAR group was reported at two years. However, the study had a number of limitations including a lack of randomisation and inclusion of only a small number of patients. Although the reported baseline characteristics are similar between the groups, further information on adjacent joint arthrosis would have been beneficial. Those patients undergoing arthrodesis were further divided into three techniques, which introduces heterogeneity amongst this arthrodesis group. Provision of outcomes for each technique would have demonstrated whether all techniques had equal effectiveness but the low number of patients studied precluded this. Again, details regarding the postoperative physiotherapy regime and those responsible for measuring outcomes should have been provided.

Krause et al., 2011. Krause et al. [28] performed a retrospective comparative study of 161 patients. No statistically significant difference in functional outcome was reported between the groups; however, TAR patients had a higher complication rate (P = 0.003). Clear indications for each procedure are set out and details regarding the surgical technique, surgeon experience, postoperative regime, and definitions of terms are given. Due to strict inclusion and exclusion criteria, only 31% of patients were deemed eligible to participate limiting the external validity of results. The authors excluded cases where a failed arthrodesis was converted to a TAR but included cases where a failed TAR was converted to AA. Conversion procedures are likely to be more complex and so, prone to worse results; the inclusion of failed TAR but not failed AA potentially increases the complexity of cases in the AA group and this may have impacted outcomes. The ankle replacement used as the intervention could be one of four prostheses depending on surgeon preference: the Agility ankle system (Depuy, Warsaw, IN, USA), the Mobility ankle system (Depuy, Warsaw, IN, USA), Scandinavian Total Ankle Replacement (STAR) (Waldmar Link, Hamburg, Germany), and HINTEGRA prosthesis (Newdeal SA, Lyon, France). This is a pragmatic approach but the outcomes of different prostheses may vary and this is not accounted for in the study. Comparison between the two groups is limited by their differences at baseline and complexity of surgery performed. The fusion group was younger, had a lower proportion of rheumatoid arthritis, and had a much higher proportion of low complexity surgery (87% versus 32%; any positive results may result from these differences rather than the type of surgery received.

Saltzman et al., 2010. Saltzman et al. [29] performed a retrospective comparative study of 71 patients undergoing either TAR or AA, using a STAR (Waldmar Link, Hamburg, Germany). A significant improvement in the TAR group in the pain component of Ankle Osteoarthritis Scale (AOS) (P = 0.001) and the mental component of SF-36 (P = 0.011) was reported. Initially, 138 patients were assessed for eligibility but 67 did not satisfy inclusion criteria and this high number questions the external validity of results. Of the 71 included, 11 were lost to follow-up, with slightly more lost in the AA group. Patients undergoing TAR with an alternative prosthesis were excluded; in contrast, those undergoing AA had three different surgical techniques performed. This approach is slightly contradictory as there is an assumption that patients having differing TAR replacements may have varying outcomes but those having various arthrodeses have equal outcomes. A pragmatic approach would be to

| Study | Reason for exclusion |
|-------|----------------------|
| Conley et al., 2012 [32] | Expert opinion |
| Flavin et al., 2013 [34] | No functional outcome recorded |
| Hahn et al., 2012 [35] | No functional outcome recorded |
| Krause and Schmid 2012 [36] | No functional outcome recorded |
| Pirion et al., 2008 [18] | No functional outcome recorded |
| Rouhani et al., 2011 [37] | Study participants divided into more than two groups |
| Rouhani et al., 2012 [38] | Study participants divided into more than two groups |
| Slobogean et al., 2010 [39] | No functional outcome recorded |
| Soo Hoo et al., 2007 [14] | No functional outcome recorded |
compare all replacements versus all arthrodeses, or alternatively to compare one replacement against one fusion technique. At the beginning of this section, the importance of randomisation and transparency of treatment allocation was discussed. In the current study, the AA group had a higher number of young patients, males, and those with posttraumatic arthritis. Each of these factors may directly influence outcome and thus any positive results cannot be confidently attributed to the treatment given. Outcome measures have only been recorded postoperatively and the lack of preoperative value limits the value of the results as the degree of improvement following treatment is not known.

4. Discussion

Four studies were identified and reviewed which addressed our research question. Two of the four studies reported statistically significant improvements in functional outcomes following TAR [27, 29]; the other two studies showed no differences between the two groups [26, 28]. However, the methodological flaws present stop definitive conclusions being drawn.

The main limitation in design common to all studies was the lack of randomisation. This risks differences in the study groups being present at the point of treatment allocation which has the potential to affect results. Only one study described the indications for the two procedures [28], using severe deformity or instability, poor ankle motion, no or mild adjacent joint arthritis, and younger age as indications of arthrodesis. Therefore, the arthrodesis group in this study will have had a higher proportion of patients with these factors than the TAR group, which all may have influenced outcomes. The other three studies [26, 27, 29] do not describe the indications used for allocation but it is likely that baseline characteristics also differed in these studies, limiting the ability to directly compare outcomes between the two groups. A further limitation of the systematic review is the use of pragmatic entry criteria for the intervention and comparator groups, with all arthrodesis procedures and any uncemented ankle replacement included. The four studies included used five different uncemented ankle prostheses and four fixation methods for arthrodesis including open and arthroscopic techniques. The inclusion of numerous surgical techniques restricts the generalisability of the results to any specific technique and it is likely that the outcomes following each method differ.

Although at least one functional outcome was measured in each study, the evidence supporting the validity, reliability, and responsiveness of the available measures following foot and ankle surgery is limited [30, 31]. The AOFAS is the most commonly used outcome measure following foot and ankle surgery [30, 31] but it relies on the observer to measure both range of motion and malalignment, risking observer bias. The AOS is patient reported which reduces the risk of observer bias and has been validated in ankle osteoarthritis, but it is not validated in the measurement of outcome following AA or TAR. Therefore, neither of the two functional measures provides an ideal measurement tool and may have contributed to inaccurate recording of outcomes. Future research should utilise an outcome tool that both is patient reported and is validated for use in this postoperative population.

At present, the evidence is insufficient to change clinical practice. Arthrodesis has been the traditional treatment of choice and will continue to be so until the literature definitively demonstrates one modality to be superior to the other. The increased rate of complications reported following TAR further supports this approach [28]. Ideally, future research will be of RCT design so that selection bias is limited and effects measured can be attributed to treatment allocation. The population treated needs to be clearly defined so that results can be applied to the readers’ practice. They should have a patient reported outcome as the defined primary outcome and the study should be adequately powered to show a statistically significant difference between the groups.

5. Conclusion

Although half of the reviewed studies report some functional improvement following total ankle replacement, the lack of high quality evidence limits a definitive conclusion being drawn. Insufficient evidence is available to decide whether total ankle replacement or ankle arthrodesis improves functional outcomes and further research in the form of robust RCTs is indicated.

Conflict of Interests

The authors have no conflict of interests to declare and received no funding during the production of this systematic review.

References

[1] C. L. Saltzman, M. B. Zimmerman, M. O’Rourke, T. D. Brown, J. A. Buckwalter, and R. Johnston, “Impact of comorbidities on the measurement of health in patients with ankle osteoarthritis,” Journal of Bone and Joint Surgery A, vol. 88, no. 11, pp. 2366–2372, 2006.
[2] A. J. Goldberg, A. MacGregor, J. Dawson et al., “The demand incidence of symptomatic ankle osteoarthritis presenting to foot & ankle surgeons in the United Kingdom,” Foot, vol. 22, no. 3, pp. 163–166, 2012.
[3] R. Thomas, T. R. Daniels, and K. Parker, “Gait analysis and functional outcomes following ankle arthrodesis for isolated ankle arthritis,” Journal of Bone and Joint Surgery A, vol. 88, no. 3, pp. 526–535, 2006.
[4] R. L. Martin, G. W. Stewart, and S. F. Conti, “Posttraumatic ankle arthritis: an update on conservative and surgical management,” Journal of Orthopaedic and Sports Physical Therapy, vol. 37, no. 5, pp. 253–259, 2007.
[5] M. T. Pyevich, C. L. Saltzman, J. J. Callaghan, and F. G. Alvine, “Total ankle arthroplasty: a unique design: two to twelve-year follow-up,” Journal of Bone and Joint Surgery A, vol. 80, no. 10, pp. 1410–1420, 1998.
[6] T. Anderson, F. Montgomery, and A. Carlsson, “Uncemented STAR total ankle prostheses: three to eight-year follow-up of fifty-one consecutive ankles,” Journal of Bone and Joint Surgery A, vol. 85, no. 7, pp. 1321–1329, 2003.
